Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
Journal of Clinical Oncology (2014)
  • Matthew Steven Davids, Harvard University
  • John Francis Seymour, Peter MacCallum Cancer Centre
  • John F. Gerecitano, Memorial Sloan Kettering Cancer Center
  • Brad S. Kahl, University of Wisconsin-Madison
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • William G. Wierda, University of Texas MD Anderson Cancer Center
  • Mary Ann Anderson, Walter and Eliza Hall Institute of Medical Research
  • Nikita Rudersdorf
  • Lori A. Gressick
  • Nicholas P. Montalvo
  • Jianning Yang
  • Ming Zhu
  • Martin Dunbar
  • Elisa Cerri, University of Chicago
  • Sari H. Enschede, Rush University Medical Center
  • Rod Humerickhouse, Roswell Park Cancer Institute
  • Andrew Warwick Roberts, University of Melbourne
Link
Disciplines
Publication Date
May 20, 2014
Citation Information
Matthew Steven Davids, John Francis Seymour, John F. Gerecitano, Brad S. Kahl, et al.. "Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses." Journal of Clinical Oncology Vol. 32 (2014) p. 8522
Available at: http://works.bepress.com/john-pagel/92/